Fame and Mortality: Evidence from a Retrospective Analysis of Singers
November 26, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Not available
Synonyms :
(4-aminobutyl) guanidine N-(4-aminobutyl) guanidine (4-aminobutyl)guanidine
Class :
Dietary supplement, biogenic amine
Brand Name :
Not available
Synonyms :
(4-aminobutyl) guanidine N-(4-aminobutyl) guanidine (4-aminobutyl)guanidine
Class :
Dietary supplement, biogenic amine
Dosage Forms & StrengthsÂ
OralÂ
1.6mg/kgÂ
6.4mg/kgÂ
1300mgÂ
2670mg Â
Neuropathic painÂ
1300mg to 2670mg orally every 24hoursÂ
CognitionÂ
1.6mg to 6.4mg orallyÂ
1300 - 2670
mg
Orally 
every 24 hours
1.6 - 6.4
mg
Orally 
every 24 hours
1300 - 2670
mg
Orally 
every 24 hours
1.6 - 6.4
mg
Orally 
Dosage Forms & StrengthsÂ
Data not availableÂ
Refer to adult dosingÂ
bradycardia-Causing Agents may enhance the bradycardic effect of Ceritinib
bradycardia-Causing Agents may enhance the bradycardic effect of ponesimod
may increase the bradycardic effect of bradycardia-causing agents
may have an increased bradycardic effect when combined with fingolimod
may have an increased bradycardic effect when combined with ponesimod
may have an increased bradycardic effect when combined with siponimod
clozapine: they may increase the bradycardic effect of Bradycardia-Causing Agents
secretin: they may increase the bradycardic effect of Bradycardia-Causing Agents
sincalide: they may increase the bradycardic effect of Bradycardia-Causing Agents
aclidinium: they may increase the bradycardic effect of Bradycardia-Causing Agents
cimetropium: they may increase the bradycardic effect of Bradycardia-Causing Agents
eluxadoline: they may increase the bradycardic effect of Bradycardia-Causing Agents
glycopyrrolate: they may increase the bradycardic effect of Bradycardia-Causing Agents
ipratropium: they may increase the bradycardic effect of Bradycardia-Causing Agents
levosulpiride: they may increase the bradycardic effect of Bradycardia-Causing Agents
atropine: they may increase the bradycardic effect of Bradycardia-Causing Agents
oxatomide: they may increase the bradycardic effect of Bradycardia-Causing Agents
potassium chloride: they may increase the bradycardic effect of Bradycardia-Causing Agents
revefenacin: they may increase the bradycardic effect of Bradycardia-Causing Agents
tiotropium: they may increase the bradycardic effect of Bradycardia-Causing Agents
umeclidinium: they may increase the bradycardic effect of Bradycardia-Causing Agents
deferiprone: it may increase the bradycardic effect of Bradycardia-Causing Agents
thalidomide: it may increase the bradycardic effect of Bradycardia-Causing Agents
dexamethasone: it may increase the bradycardic effect of Bradycardia-Causing Agents
azelastine: it may increase the bradycardic effect of Bradycardia-Causing Agents
bradycardia causing agents increase the arrhythmia-causing effect of fexinidazole
may enhance the effect of other bradycardia agents
may enhance the effect of other bradycardia agents
may enhance the effect of other bradycardia agents
may enhance the effect of other bradycardia agents
may enhance the effect of other bradycardia agents
may have an increased bradycardic effect when combined with other bradycardia-causing agents
arrhythmogenic effects of agmatine may be enhanced with acebutolol
the severity of hypoglycemia may be elevated when agmatine is coadministered with acarbose
an increase in adverse effects severity can be noticed when agmatine is coadministered with aclidinium
an increase in the serum concentration of agmatine is seen when taken with amantadine
arrhythmogenic effects of agmatine may be enhanced with atenolol
the activity of bisacodyl can be reduced when administered with agmatine
an increase in severity of adverse effects can be seen when brompheniramine is administered with agmatine
the therapeutic activity of agmatine may be reduced with calcium gluconate
an increase in hyperkalemia severity can be seen when sulindac is administered with agmatine
an increase in severity of adverse effects can be seen when agmatine is administered with tramadol
an obstruction of neuromuscular activity of tubocurarine may be increased when combined with agmatine
arrhythmogenic activity of agmatine may be enhanced with xylometazoline
may enhance the effect of other bradycardia agents
may enhance the effect of other bradycardia agents
may enhance the effect of other bradycardia agents
may enhance the effect of other bradycardia agents
may enhance the effect of other bradycardia agents
bradycardia-causing agents increase the efficacy of ivabradine
may increase the bradycardic effect of bradycardia-causing agents
may enhance the bradycardic effect of bradycardia-causing agents
may increase the hypotensive effect of blood pressure lowering agents
may increase the bradycardic effect of each other
midodrine: they may increase the bradycardic effect of Bradycardia-Causing Agents
ozanimod: they may increase the bradycardic effect of Bradycardia-Causing Agents
tofacitinib: they may increase the bradycardic effect of Bradycardia-Causing Agents
it may diminish the excretion rate when combined with Growth hormone agonist, resulting in an enhanced serum level
it may diminish the excretion rate when combined with Growth hormone agonist, resulting in an enhanced serum level
it may diminish the excretion rate when combined with Growth hormone agonist, resulting in an enhanced serum level
it may diminish the excretion rate when combined with Growth hormone agonist, resulting in an enhanced serum level
It may enhance the risk of adverse effects when combined with Androgens
It may enhance the risk of adverse effects when combined with Androgens
may have an increased bradycardic effect when combined with other bradycardia-causing agents
amifampridine: they may increase the bradycardic effect of Bradycardia-Causing Agents
dipyridamole: they may increase the bradycardic effect of Bradycardia-Causing Agents
mirabegron: they may increase the bradycardic effect of Bradycardia-Causing Agents
nitroglycerin: they may increase the bradycardic effect of Bradycardia-Causing Agents
succinylcholine: they may increase the bradycardic effect of Bradycardia-Causing Agents
topiramate: they may increase the bradycardic effect of Bradycardia-Causing Agents
fluorouracil: they may increase the bradycardic effect of Bradycardia-Causing Agents
methoxsalen: they may increase the bradycardic effect of Bradycardia-Causing Agents
porfimer: they may increase the bradycardic effect of Bradycardia-Causing Agents
pamidronate: it may enhance the bradycardic effect of Bradycardia-Causing Agents
valerian: it may enhance the bradycardic effect of Bradycardia-Causing Agents
zoledronic acid: it may enhance the bradycardic effect of Bradycardia-Causing Agents
Actions and spectrum:Â
Agmatine regulates cardiovascular system, lowering blood pressure, reducing oxidative stress, increasing glomerular filtration, and supports hypoglycemic state potentially aiding in neurological and brain disorders.Â
Frequency not definedÂ
NauseaÂ
Stomach upsetÂ
DiarrheaÂ
Black Box Warning Â
NoneÂ
Contraindication/Caution:Â
Contraindication:Â
Cancer therapyÂ
DiabetesÂ
Immunocompromised patientsÂ
Pregnancy consideration:Â Â
USFDA pregnancy category: not assignedÂ
Lactation:Â Â
unknownÂ
Pregnancy category:Â Â
Category A: Studies that were well-controlled and met expectations revealed no risk to the foetus `in either the first or second trimester.Â
Category B: There were a lack of studies on pregnant women and no evidence of risk to the foetus in animal experiments.  Â
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.   Â
Category D: adequate data with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.  Â
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.   Â
Category N: There is no data available for the drug under this category Â
Pharmacodynamics:Â
Agmatine is derived from L-arginine an endogenous neuromodulator with affinity for various transmembrane receptors.Â
Pharmacokinetics:Â
Study data not availableÂ
Elimination and excretionÂ
Half life is 2hoursÂ
Administration:Â
Agmatine is administered orally after a mealÂ
Patient information leafletÂ
Generic Name: agmatineÂ
Why do we use agmatine?Â
Agmatine is a neuroprotective agent that treats depression and nerve pain also enhances the athletic performance. It is being researched for neuroprotection, diabetes, and psychiatric conditions.Â
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
